Pipeline

At GSK, our pipeline is focused on unlocking the science of the immune system, human genetics, and advanced technologies to develop vaccines and specialty medicines.

Our products in development progress through three stages: phase I, phase II, and phase III/registrational. Each of these phases allows us to assess the safety and efficacy of our investigational products to eventually provide data to support applications for regulatory approval.

DISEASE STATES

Complicated Urinary Tract Infection
Phase 3

Tebipenem

ADAPT PO: Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Tebipenem Compared to IV Ertapenem in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis

PIVOT PO: A Study of Oral Tebipenem Pivoxil Hydrobromide Compared to Intravenous Imipenem-Cilastatin in Participants With Complicated Urinary Tract Infection or Acute Pyelonephritis

COMPLICATED VULVOVAGINAL CANDIDIASIS
Phase 3

Ibrexafungerp

VANQUISH: Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

COVID-19
Phase 1

Antiviral Monoclonal Antibody (Vir-7832)

AGILE (Early Phase Platform Trial for COVID-19)

COVID-19
Phase 2

Antiviral Monoclonal Antibody (Vir-7832)

AGILE (Early Phase Platform Trial for COVID-19)

GONORRHEA
Phase 3

Gepotidacin

A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea

PULMONARY ASPERGILLOSIS
Phase 2

Ibrexafungerp

SCYNERGIA: Study to Evaluate the Safety and Efficacy of the Coadministration of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis (SCYNERGIA)

REFRACTORY FUNGAL DISEASE
Phase 3

Ibrexafungerp

FURI: Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

UNCOMPLICATED URINARY TRACT INFECTION
Phase 1

GSK3882347 (FimH Antagonist)

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections

UNCOMPLICATED URINARY TRACT INFECTION
Phase 3

Gepotidacin

A Study to Evaluate Efficacy and Safety of GEPOTIDACIN in the Treatment of Uncomplicated Urinary Tract Infection

Comparative Study to Evaluate Efficacy and Safety of GEPOTIDACIN to NITROFURANTOIN in Treatment of Uncomplicated Urinary Tract Infection

INVASIVE CANDIDIASIS
Phase 3

Ibrexafungerp

CARES: Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris

MARIO: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

0 results - Use filter to search Pipeline

Disclaimer

This document contains information for healthcare providers and is intended solely for educational purposes. This display includes ongoing clinical trials for both approved and investigational compounds.

Some agents are approved in select indications. Inclusion in this display does not imply regulatory approval for these compounds or all indications. Information about all trials can be found at www.clinicaltrials.gov.